Nest.Bio Ventures
VC Fund
Boston, United States
Nest.Bio Ventures is a VC fund in Boston focused on Biotechnology and Therapeutics. Nest.Bio Ventures takes a deep science, cross-border approach to translating breakthrough science into revolutionary companies.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nest.Bio Ventures invests in
Stages Nest.Bio Ventures invests in
Countries Nest.Bio Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cheryl Cui
|
|||
Ely Porter
|
|||
Xi Chen
|
|||
Investment Focus
Industry
- Biotechnology 9 (50%)
- Therapeutics 4 (22%)
- Health Care 3 (17%)
- Artificial Intelligence 3 (17%)
- Medical 2 (11%)
Stage
- Series A 8 (44%)
- Seed 5 (28%)
- Series B 3 (17%)
Country
- United States 7 (39%)
- China 2 (11%)
- France 1 (6%)
- Singapore 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Cheryl Cui
Partner
|
Partner | Total investments: 0 | Find email | |
|
Ely Porter
Team Member
|
Team Member | Total investments: 0 | Find email | |
Jeffrey Lu
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Xi Chen
Team member / Venture Partner
|
Team member / Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DeepVerse
|
DeepVerse "magic technology" takes materials informatics as the background, combines artificial intelligence, computational physics, high-throughput experiments, and other cutting-edge technologies, integrates cross-field data, conducts forward prediction and reverse design, and accelerates the industrial implementation of new materialresearch and development technologies, aiming to provide the industry with "problem-oriented" breakthrough solutions. | Seed / Mar 14, 2023 | |
PAQ Therapeutics
|
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation. | $30M / Series A / Jul 15, 2021 | |
Engine Biosciences
|
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $43M / Series A / May 26, 2021 | |
Senti Biosciences
|
Senti Biosciences is a developer of a programmable biology platform for cancer therapies. Its therapeutics specialize in cell engineering and biological programming to build the future of gene and cell-based therapies that enable physicians to give patients life-saving treatments at an affordable cost. | $105M / Series B / Jan 06, 2021 | |
Bota Biosciences
|
Bota Biosciences (Bota Bio) is a global industrial biotechnology company connecting biological design to scale-up manufacturing to accelerate shifts to sustainable living. Bota has built an integrative bioengineering platform, to develop and implement efficient, eco-friendly, and cost-effective biomanufacturing technologies. Committed to itsmission, Bota established its own pilot plant and manufacturing facility, affirming its dedication to offering scalable industrial solutions and market-ready products. This infrastructure strengthens support for customers and partners across industries such as nutrition, food, personal care, and animal health. Powered by a dynamic, multidisciplinary team, Bota Bio channels biotech innovations to create a global impact. The company's Series B financing has surpassed $100 million, bringing its aggregate funding to $145 million, with investment from notable strategic and financial investors, including Hong Shan Capital, Matrix Partners, and BASF Ventures. | $15M / Series A / Sep 25, 2020 | |
RootPath
|
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer. | $11M / Series A / Jan 05, 2020 | |
Platelet BioGenesis
|
Platelet BioGenesis specializes in the fields of biotechnology, platelets, and drug discovery. They discover a new category in therapeutics. The company is developing technology to produce donor-independent human platelets from human induced pluripotent stem cells. | Series A / Sep 09, 2019 | |
|
RootPath
|
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer. | $7M / Seed / Aug 30, 2018 | |
POINTS Technology
|
POINTS is the first truly scalable blockchain data collaboration protocol , Points is the Next generation blockchain-based credit service network High-performance, secure, AI-empowered, decentralized financial services for consumers | $8M / Seed / Jul 20, 2018 | |
HiFiBiO Therapeutics
|
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rootedbiological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France. | $37.5M / Series B / May 16, 2018 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Nest.Bio Ventures invest in?
Nest.Bio Ventures invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Seed stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nest.Bio Ventures?
Public channels for Nest.Bio Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nest.Bio Ventures?
The team at Nest.Bio Ventures includes Cheryl Cui (Partner), Ely Porter (Team Member) and Jeffrey Lu (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
